Skip to main content
. 2019 Feb 28;51(3):24. doi: 10.1038/s12276-019-0221-7

Table 2.

Clinical response to apatinib in patients with metastatic sarcoma

Response 12 W Overall response
CR 0 0
PR 10 9
SD 41 25
PD 8 25
Excluded 5 5
ORR 16.95% (10/59) 15.25% (9/59)
DCR 86.44% (41/59) 57.63% (34/59)
PFR-12W = 74%, OSR-12W = 92% mPFS = 7.93 m, mOS = 17.27 m

CR complete response, PR partial response, SD stable disease, PD progressive disease, DCR disease control rate, ORR objective response rate, PFR progression-free survival rate, mPFS median progression-free survival